Martin Aringer
A5091190600- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Systemic Sclerosis and Related Diseases
- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- Cytokine Signaling Pathways and Interactions
- Autoimmune and Inflammatory Disorders Research
- Lymphoma Diagnosis and Treatment
- Atherosclerosis and Cardiovascular Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Spondyloarthritis Studies and Treatments
- Vasculitis and related conditions
- Immunodeficiency and Autoimmune Disorders
- Immune Cell Function and Interaction
- Inflammatory Myopathies and Dermatomyositis
- Urticaria and Related Conditions
- Chronic Lymphocytic Leukemia Research
- Inflammasome and immune disorders
- Musculoskeletal Disorders and Rehabilitation
- Gout, Hyperuricemia, Uric Acid
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Peripheral Neuropathies and Disorders
- Otitis Media and Relapsing Polychondritis
- Autoimmune Bullous Skin Diseases
- Renal Diseases and Glomerulopathies
University Hospital Carl Gustav Carus
2016-2025
TU Dresden
2016-2025
Klinik und Poliklinik für Psychotherapie und Psychosomatik
2016-2025
Center for Rheumatology
2001-2024
Deutsche Gesellschaft für Urologie
2016-2023
Technical University of Munich
2023
Stuttgart Observatory
2022
Inter 3
2022
University Medical Center
2015-2021
GTx (United States)
2018-2020
To provide an update of the European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) management recommendations to account for most recent developments in field.An international task force considered new evidence supporting or contradicting previous and novel therapies strategic insights based on two systematic literature searches efficacy safety disease-modifying antirheumatic drugs (DMARDs) since last (2016) until 2019. A predefined voting process was applied, current levels...
To develop new classification criteria for systemic lupus erythematosus (SLE) jointly supported by the European League Against Rheumatism (EULAR) and American College of Rheumatology (ACR).This international initiative had four phases. 1) Evaluation antinuclear antibody (ANA) as an entry criterion through systematic review meta-regression literature generation Delphi exercise, early patient cohort, a survey. 2) Criteria reduction nominal group technique exercises. 3) definition weighting...
Our objective was to update the EULAR recommendations for management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity prevention flares. Hydroxychloroquine is recommended all patients with lupus, dose not exceeding 5 mg/kg real body weight. During chronic...
Giant-cell arteritis commonly relapses when glucocorticoids are tapered, and the prolonged use of is associated with side effects. The effect interleukin-6 receptor alpha inhibitor tocilizumab on rates relapse during glucocorticoid tapering was studied in patients giant-cell arteritis.In this 1-year trial, we randomly assigned 251 patients, a 2:1:1:1 ratio, to receive subcutaneous (at dose 162 mg) weekly or every other week, combined 26-week prednisone taper, placebo taper over period either...
Objectives To develop recommendations for the management of adult and paediatric lupus nephritis (LN). Methods The available evidence was systematically reviewed using PubMed database. A modified Delphi method used to compile questions, elicit expert opinions reach consensus. Results Immunosuppressive treatment should be guided by renal biopsy, aiming complete response (proteinuria <0.5 g/24 h with normal or near-normal function). Hydroxychloroquine is recommended all patients LN. Because...
Objectives To develop recommendations for the diagnosis, prevention and treatment of neuropsychiatric systemic lupus erythematosus (NPSLE) manifestations. Methods The authors compiled questions on prevalence risk factors, diagnosis monitoring, therapy prognosis NPSLE. A systematic literature search was performed evidence categorised based sample size study design. Results Systemic (SLE) patients are at increased several Common (cumulative incidence >5%) manifestations include...
Objective To update the 2012 EULAR/ERA–EDTA recommendations for management of lupus nephritis (LN). Methods Following EULAR standardised operating procedures, a systematic literature review was performed. Members multidisciplinary Task Force voted independently on their level agreeement with formed statements. Results The changes include treatment targets, use glucocorticoids and calcineurin inhibitors (CNIs) end-stage kidney disease (ESKD). target therapy is complete response (proteinuria...
Objectives To assess the effects of Rituximab (RTX) on skin and lung fibrosis in patients with systemic sclerosis (SSc) belonging to European Scleroderma Trial Research (EUSTAR) cohort using a nested case-control design. Methods Inclusion criteria were fulfilment American College Rheumatology classification for SSc, treatment RTX availability follow-up data. RTX-treated matched control from EUSTAR database not treated RTX. Matching parameters skin/lung modified Rodnan Skin Score (mRSS),...
Objectives To update the EULAR recommendations for management of systemic lupus erythematosus (SLE) based on emerging new evidence. Methods An international Task Force formed questions systematic literature reviews (January 2018–December 2022), followed by formulation and finalisation statements after a series meetings. A predefined voting process was applied to each overarching principle recommendation. Levels evidence strengths recommendation were assigned, participants finally provided...
Objective To achieve consensus on a definition of remission in SLE (DORIS). Background Remission is the stated goal for both patient and caregiver, but has been lacking. Previously, an international task force consisting representatives medical specialists published framework such definition, without reaching final recommendation. Methods Several systematic literature reviews were performed specific research questions examined suitably chosen data sets. The findings discussed, reformulated...
Genome integrity is continuously challenged by the DNA damage that arises during normal cell metabolism. Biallelic mutations in genes encoding genome surveillance enzyme ribonuclease H2 (RNase H2) cause Aicardi-Goutières syndrome (AGS), a pediatric disorder shares features with autoimmune disease systemic lupus erythematosus (SLE). Here we determined heterozygous parents of AGS patients exhibit an intermediate phenotype and demonstrated genetic association between rare RNASEH2 sequence...
Objective To investigate the risk of developing lower intestinal perforations (LIPs) in patients with rheumatoid arthritis (RA) treated tocilizumab (TCZ). Methods In 13 310 RA observed German biologics register R heumatoid A rthritis: O b servation Bi ologic T herapy, 141 serious gastrointestinal events possibly associated were reported until 31 October 2015. All validated independently by two physicians, blinded for treatment exposure. Results 37 LIPs (32 colon/sigma) 53 972 patient years...
To analyze the efficacy and safety of nintedanib in patients with fibrosing autoimmune disease-related interstitial lung diseases (ILDs) a progressive phenotype.The INBUILD trial enrolled ILD other than idiopathic pulmonary fibrosis, diffuse disease >10% extent on high-resolution computed tomography, forced vital capacity percent predicted (FVC%) ≥45%, diffusing lungs for carbon monoxide ≥30% to <80%. Patients fulfilled protocol-defined criteria progression within 24 months before screening,...